Please login to the form below

Not currently logged in
Email:
Password:

Sinclair and IS plan to merge

Sinclair Pharma has announced plans for a potential merger with IS Pharma to create a new Europe-wide speciality pharma company

Sinclair Pharma and IS Pharma are in 'advanced discussions' regarding the creation of a new Europe-wide speciality pharma company, according to a statement from Sinclair.

Sinclair IS Pharma, as the new company is planned to be named, would be headquartered in the UK, with a focus on developing products in dermatology and specialist hospital therapies.

Existing therapies from the portfolios of both Sinclair and IS would continue to be developed and marketed, with the new combined company also having in-house development capability.

As it stands, a deal would be an all-share offer from Sinclair, with IS shareholders receiving 2.69 Sinclair shares per one IS share.

Shareholders of Sinclair would own 62.4 per cent of the new company while IS shareholders would have 37.6 per cent.

As well as covering Europe, Sinclair said following the proposed merger, the new company 'would continue to access the substantial growth opportunities in emerging markets through existing and new regional strategic partnerships'.

Any deal depends on a unanimous recommendation by the board of IS regarding any offer from Sinclair.

14th February 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics